Welcome to our dedicated page for Roivant Sciences news (Ticker: ROIV), a resource for investors and traders seeking the latest updates and insights on Roivant Sciences stock.
Roivant Sciences (ROIV) is a commercial-stage biopharmaceutical company pioneering accelerated drug development through its innovative 'vant' subsidiary model. This dedicated news hub provides investors and industry stakeholders with timely updates on clinical milestones, regulatory developments, and strategic partnerships.
Our curated collection of ROIV press releases and verified news articles serves as a comprehensive resource for tracking the company's progress in immunology, dermatology, and autoimmune therapeutics. Users will find updates spanning clinical trial results, FDA communications, licensing agreements, and operational developments across Roivant's network of specialized subsidiaries.
The page features essential updates including new drug applications, partnership announcements with academic institutions, and pipeline expansion into novel therapeutic areas. All content is organized chronologically to help users monitor the company's execution of its unique drug development strategy.
Bookmark this page for direct access to primary source materials from Roivant Sciences, including SEC filings and peer-reviewed research collaborations. Check regularly for updates on how the company's agile approach continues to reshape biopharmaceutical innovation.
Roivant (Nasdaq: ROIV) and Priovant Therapeutics announced breakthrough results from their Phase 3 VALOR study of brepocitinib in treating dermatomyositis (DM). The once-daily oral 30mg dose demonstrated significant superiority over placebo, achieving a week 52 mean Total Improvement Score (TIS) of 46.5 versus 31.2 (p=0.0006).
Key highlights include: 62% of brepocitinib patients reduced steroid use to ≤2.5 mg/day (vs 34% placebo), over two-thirds achieved moderate response (TIS≥40), and nearly half showed major response (TIS≥60). The drug demonstrated rapid onset, with significant improvements visible by week 4. Among patients with moderate-to-severe skin disease, 44% achieved cutaneous clinical remission by week 52 (vs 21% placebo).
The safety profile aligned with previous trials, and Priovant plans an NDA filing in the first half of 2026.
Roivant (Nasdaq: ROIV) has been recognized on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List, ranking 28th place in the small & medium category. This marks the company's first appearance on this prestigious list.
The selection process involved analyzing survey responses from nearly 40,000 employees across Great Place To Work Certified companies in the biotech and pharmaceutical industry. The evaluation was based on the Trust Index Survey, which considered data from over 1.3 million survey responses representing more than 8.4 million employees.
Immunovant (Nasdaq: IMVT) has revealed promising six-month remission data for batoclimab in treating uncontrolled Graves' disease. In a proof-of-concept study, approximately 80% (17/21) of patients maintained normal thyroid function six months after treatment cessation, with 50% (8/17) of responders achieving anti-thyroid drug (ATD) free remission.
The study involved a 24-week treatment period with batoclimab administered subcutaneously, followed by a 24-week off-treatment follow-up. The treatment demonstrated strong durability, with an additional 30% (5/17) of responding patients requiring only minimal ATD doses. Safety and tolerability were consistent with previous batoclimab studies.
Two potentially registrational trials for IMVT-1402, the company's lead compound, are currently enrolling patients, with topline results expected in 2027.
Roivant Sciences (Nasdaq: ROIV) reported Q1 2025 financial results and business updates. The company maintained a strong financial position with $4.5 billion in consolidated cash and marketable securities as of June 30, 2025. Key highlights include completion of a $1.5 billion share repurchase program, reducing outstanding shares by over 15%, and board approval for an additional $500 million buyback program.
Financial results showed R&D expenses increased to $152.9 million from $120.5 million year-over-year, while G&A expenses rose to $134.0 million. The company reported a net loss from continuing operations of $273.9 million ($0.33 per share).
Clinical progress remains on track with multiple milestone readouts expected, including brepocitinib's Phase 3 VALOR study in dermatomyositis in H2 2025 and IMVT-1402's advancement in six indications.
Roivant (Nasdaq: ROIV) has scheduled a conference call and webcast for Monday, August 11, 2025, at 8:00 a.m. ET to discuss its financial results for the first quarter ended June 30, 2025, and provide a business update. Investors can access the call by registering through an online link, and presentation materials will be available in the Investors section of Roivant's website. The webcast recording will be archived on the company's website following the event.
Roivant (ROIV) has scheduled a conference call and webcast for Thursday, May 29, 2025, at 8:00 a.m. ET to discuss its financial results for the fourth quarter and fiscal year ended March 31, 2025, along with a business update. Interested participants can register for the phone conference through an online registration link. The presentation materials and webcast access will be available in the Investors section of Roivant's website under "Events & Presentations." Following the event, an archived version of the webcast will be accessible on the company's website.
Immunovant (IMVT) announced significant leadership changes and expansion of its IMVT-1402 development program. Eric Venker, M.D., currently President and COO of Roivant, has been appointed as Immunovant's CEO, replacing Pete Salzmann who retired from his role as CEO and Director. Additionally, Tiago Girao was appointed as CFO, succeeding Renee Barnett.
The company revealed two new indications for IMVT-1402: Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE). An IND has been cleared for a potentially registrational program in SjD, with studies expected to begin in summer 2025. A proof-of-concept study has been initiated in CLE, marking the drug's sixth indication.
The company confirms its current cash balance will support operations through the expected Graves' Disease readout in 2027. These changes are part of a broader strategic transition with Roivant increasing its operational involvement and strategic oversight of Immunovant.
Immunovant (IMVT) has announced positive results from two key clinical studies. The Phase 3 study of batoclimab in Myasthenia Gravis (MG) met its primary endpoint, showing significant improvements in MG-ADL scores: a 5.6-point improvement in the higher dose arm (74% IgG reduction) and a 4.7-point improvement in the lower dose arm (64% IgG reduction).
The initial results from Period 1 of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Phase 2b study demonstrated an average improvement of 1.8 in adjusted INCAT disability scores across batoclimab arms. Notably, an 84% responder rate was observed in patients achieving over 70% IgG reduction.
Both studies confirmed that deeper IgG reductions correlated with better clinical outcomes. The company plans to initiate pivotal studies for their lead asset IMVT-1402 in both MG and CIDP indications.
FAQ
What is the current stock price of Roivant Sciences (ROIV)?
What is the market cap of Roivant Sciences (ROIV)?
